Skip to main content

FDA recall, , Moderate risk

Rising Pharmaceuticals Temozolomide Capsules, 5mg

Temozolomide Capsules failed impurities and degradation specifications during stability testing.

What happened

Rising Pharma Holding, Inc., of East Brunswick, New Jersey, recalled Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, after an out-of-specification result was observed during 9th-month long term stability testing for impurities and degradation specifications. The recall began on March 3, 2026, and was added to the FDA's Enforcement Report on March 4, 2026.

The product was distributed nationwide within the U.S. The recalled capsules are manufactured for Rising Pharmaceuticals, Inc., Allendale, NJ 07401, with a country of origin of Taiwan. The recall involves 1200 bottles.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is yours affected?

Match the NDC and lot code listed under your product.

An NDC (National Drug Code) is usually printed on the drug's label.

  1. Temozolomide Capsules, 5mg

    NDC
    • 16571-816-51
    Lot code
    • 1TM0524003A

Recall details

Company began the recall
Sold in

Nationwide within the U.S

Company
Rising Pharma Holding, Inc.East Brunswick, New Jersey
Risk

Moderate risk

Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

Event ID
98523
Recall number
D-0384-2026
Quantity recalled
1200 bottles

All recalls from Rising Pharma Holding, Inc.

Timeline

FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.

  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. In FDA's weekly enforcement report

  4. Listed on Recall Canary

  5. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 2, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)